StemCell Longevita
Safety Guide
7 min read

Заболевания сердца Stem Cell Therapy — Risks, Side Effects & Safety Profile

Медицинская проверка Медицинская команда SCL
Share:
Summarize with AI:

Safety Summary

Published clinical trials demonstrate MSC therapy for heart disease & cardiovascular conditions has an excellent safety profile. No serious adverse events have been reported in major studies. Side effects are mild and temporary.

Known Side Effects of Заболевания сердца Stem Cell Therapy

Based on published clinical trial data, the following side effects have been reported with mesenchymal stem cell (MSC) therapy for heart disease & cardiovascular conditions:

Mild chest discomfort for 24–48 hours post-treatment (not cardiac in nature)
Brief arrhythmia episodes during IV infusion (monitored, self-resolving)
Fatigue and mild headache for 1–2 days
No myocardial damage reported in published cardiac MSC trials
Treated in JCI-accredited cardiac units with full monitoring capability

Safety Standards at StemCell Longevita

JCI-Accredited Hospitals

All procedures performed in Joint Commission International accredited facilities — the gold standard for healthcare quality and patient safety worldwide.

GMP-Certified Cell Processing

Stem cells processed in Good Manufacturing Practice certified laboratories with rigorous quality control, sterility testing, and viability verification for every batch.

Comprehensive Screening

Every patient undergoes thorough pre-treatment screening including blood work, medical history review, and condition-specific diagnostics to ensure treatment suitability.

12-Month Monitoring

Every patient receives a 12-month post-treatment monitoring program with regular telemedicine check-ins to track progress and address any concerns.

Who Should Not Receive Stem Cell Therapy

While MSC therapy is safe for most patients, certain conditions may be contraindications:

  • Active cancer or ongoing chemotherapy/radiation treatment
  • Active systemic infections requiring IV antibiotics
  • Severe organ failure (end-stage kidney, liver, or heart failure)
  • Pregnancy or planned pregnancy within 3 months
  • Known allergy to any component used in cell processing

Our medical team conducts a thorough screening process to identify any contraindications before treatment. If stem cell therapy is not appropriate for your situation, we will advise you honestly.

Часто задаваемые вопросы

Published Phase I/II clinical trials demonstrate excellent safety for cardiac MSC therapy. Treatments are performed in JCI-accredited cardiac units with continuous cardiac monitoring. No serious adverse events related to MSC therapy have been reported in major cardiac studies.

Have Safety Questions?

Our medical team is available to discuss any concerns about risks, side effects, or treatment suitability for your specific condition.

Related Pages

Medical Disclaimer: This page provides evidence-based information compiled from published clinical literature. Individual results may vary. This content does not constitute medical advice. Consult with qualified healthcare professionals before making treatment decisions. StemCell Longevita operates as an international patient coordination platform.

Related pages